METHODS OF TREATING HEMATOLOGIC CANCERS
The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.
1 . A method of treating a hematologic cancer in a subject comprising:
(a) administering to the subject an effective amount of a purine nucleoside phosphorylase (PNP) inhibitor; and
(b) administering to the subject an effective amount of an alkylating agent or an anti-CD20 agent.
2 . A method of treating a hematologic cancer in a subject comprising:
(a) administering to the subject an effective amount Forodesine; and
(b) administering to the subject an effective amount of Rituximab.
3 . The method of claim 2 further comprising administering to the subject an effective amount of an alkylating agent.
4 . The method of claim 3 , wherein the alkylating agent is selected from a mustard derivative, a nitrosourea derivative, a platinum compound, and an imidazole carboxamide compound.
5 . The method of claim 3 , wherein the alkylating agent is a mustard derivative.
6 . The method of claim 3 , wherein the alkylating agent is Bendamustine.
7 . The method of claim 2 , wherein Forodesine and Rituximab are administered concurrently.
8 . The method of claim 2 , wherein Forodesine and Rituximab are administered sequentially.
9 . The method of claim 2 , wherein the Rituximab is administered one or more times prior to administration of Forodesine.
10 . The method of claim 2 , wherein the hematologic cancer non-Hodgkin's lymphoma.
11 . The method of claim 2 , wherein the hematologic cancer is chronic lymphocytic leukemia.
12 . The method of claim 2 , wherein the hematologic cancer is acute lymphoblastic leukemia.
13 . The method of claim 3 , wherein Forodesine, Rituximab and the alkylating agent are administered concurrently.
14 . The method of claim 3 , wherein Forodesine, Rituximab and the alkylating agent are administered sequentially.
15 . The method of claim 14 , wherein Rituximab and the alkylating agent are administered one or more times prior to administration of Forodesine.
16 . The method of claim 2 , wherein the subject resistant to one or more chemotherapeutic agents.
17 . A pharmaceutical composition comprising Forodesine and Rituximab.
18 . The composition of claim 17 further comprising an alkylating agent.
19 . The composition of claim 18 that comprises Forodesine, Bendamustine, and Rituximab.
20 . A kit comprising Forodesine and Rituximab.
21 . The kit of claim 20 , further comprising an alkylating agent.
22 . The kit of claim 20 , further comprising a delivery system for at least one of Forodesine, Rituximab, and the alkylating agent.
23 . The kit of claim 20 , further comprising instructions for treating a subject.
24 . The kit of claim 21 that comprises Forodesine, Rituximab and Bendamustine.